Anti-Beta2-Glycoprotein 1 IgM ELISA Assay Kit

$280.00

The Eagle Biosciences DIASTAT® Anti-β2-glycoprotein 1 IgM (β2-GP1 IgM) test is a semi-quantitative enzyme-linked immunosorbent assay (ELISA) for the detection of the IgM class of autoantibodies specific for β2-GP1 antigen in human serum or sodium citrate, EDTA (K2) and lithium heparin anti-coagulated plasma. It is intended to aid in the assessment of thrombotic risk in patients with autoimmune disease associated with thrombotic disorders such as primary antiphospholipid syndrome or secondary to systemic lupus erythematosus. It is not definitive in isolation. Autoantibody levels represent one parameter in a multicriterion diagnostic process. The Eagle Biosciences Anti-β2-glycoprotein 1 IgM ELISA Assay Kit is for Research Use Only.

SKU: FBGP100M Categories: , ,

Total Complement Functional Screen ELISA

For Research Use Only

Size: 1×96 wells
Sensitivity: See Package Insert
Dynamic Range: Cut-off
Incubation Time: 2 hours
Sample Type: Serum, Plasma
Sample Size: 10 µL

Controls Included

Product manufactured in Sweden by Svar Life Science

Additional Information

Assay Background

β2-glycoprotein 1 (β2GP1), or apolipoprotein H, is a plasma glycoprotein that circulates at approximately 200μg/ml1. It is associated with plasma lipoproteins, in particular very low-density lipoprotein, and may regulate haemostatic actions occurring on the lipoprotein surface2. β2GP1 has been shown to inhibit the intrinsic coagulation pathway via inhibition of Factor XII activation on negatively charged surfaces, and is the dominant antigen for antiphospholipid antibodies (APAs) in patients with anti-phospholipid syndrome3.

The presence of APAs such as anti-cardiolipin antibodies is associated with venous and arterial thrombosis, recurrent spontaneous abortions and thrombocytopenia. Anti-cardiolipin antibodies are also present in response to a variety of infections and certain drug treatments. APAs associated with infections are usually transient and not associated with thromboembolic complications; APAs in autoimmune disease are often associated with thromboembolic disease4.

Although the mechanism of APA binding is poorly understood, it has been demonstrated that APAs may bind directly to phospholipid or via a protein co-factor, most commonly β2GP1. β2GP1 is often included in anti-cardiolipin assays to ensure the detection of both β2GP1-dependent and β2GP1-independent antibodies. β2GP1-dependent APAs tend to be associated with autoimmune disease; β2GP1-independent APAs tend to be associated with infection3,4. A number of studies have demonstrated that detection of β2GP1 antibodies, in conjunction with anticardiolipin measurement, is important in defining the thrombotic risk associated with APAs5.

Assay Principle

The wells of the microtitre strips are coated with highly purified human β2GP1 antigen. During the first incubation, specific autoantibodies in diluted serum or plasma bind to the antigen-coated surface. The wells are then washed to remove unbound components. In the second incubation, the Conjugate, an enzyme-labeled monoclonal antibody to human IgM, binds any surface-bound autoantibodies. After further washing, specific autoantibodies are traced by incubation with the Substrate. Addition of Stop Solution terminates the reaction, resulting in a colored end-product. The amount of Conjugate bound is measured in absorbance units. In the qualitative protocol, the amount of Conjugate bound by the sample is compared with that bound by the Reference Control. In the semi-quantitative protocol, the concentration of anti-β2GP1 autoantibody can be estimated by interpolation from a dose-response curve based on Standards formulated from a high titer plasma and assigned arbitrary units (U/mL).

Manual

Product Manual